Redeye comments on Isofol’s announcement of the outcome of its TO1 warrant exercise.
Redeye shares its view on Sleep Cycle ahead of the Q1 report, as the company’s evolution into a dive...
A directed issue of SEK2.55m, settled via debt offset by insiders, provides some balance sheet relie...
Redeye retains its positive view and Base Case in q.
* Strong A15 contribution, ’26e production up ~20% * Recent Brage updates imply ~NOK 0.
* Q1: Sales of EUR 44m (39m), EBIT of EUR 2.5m (0.8m) * 4% '26e EBIT raised following continued stre...
* Q1e sales SEK 8m (10m), EBIT SEK -12m (-14m) * Softer quarter due to absence of machine orders * T...
Endomines CMD provided a solid presentation of current operations and future plans and demonstrated ...
Marknaden prisar aktien på historiska sänken. När den underliggande lönsamheten blottläggs framträde...
Redeye updates its estimates and valuation on W5 Solutions following the acquisition of KT Shelter, ...
* CEO Joakim Nydemark comments in a video interview * Four strategic reason for the proposed deal * ...
Physitrack has announced two new agreements in Switzerland within its Lifecare division, signaling a...
While we believe there are growth levers in the existing business, we think further license deals ar...
Nettoomsättningen uppgick till 80,1 MSEK (67,3) i det tredje kvartalet (november–januari) i Vuxen Gr...
VBG Group redovisar ett stabilt Q4 med omsättning på 1 312 MSEK (+2,8%), men påverkas negativt av sv...
Magle has announced a rights issue aimed at strengthening its balance sheet, improving financial fle...
Redeye comments on Fractal's press release confirming the termination of IEEPA tariffs and the exemp...
Redeye comments on Smart Eye's SEK40m agreement with a European police authority for AI-based drug i...
We expect PFPM/share growth of 17% y/y in Q1, driven by higher NOI, lower financial expenses, and bu...
Redeye updates on Genovis following a new announcement.